An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
India has delivered the strong performance at the ISSF Junior World Cup 2026 in the…
Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is the largest pharmaceutical company in…
Sabastian Sawe has achieved the historical achievement as he completed the an official marathon in…
Andhra Pradesh state government has announced the first Mushroom Mission with the investment around the…
The Delhi Metro Rail Corporation (DMRC) has appointed Mr. Sanjay Jamuar as the first Chief…
The French President Emmanuel Macron has said that he will step away from the politics…